Oncopeptides announces today that the first patient has been dosed in the pivotal phase III study OCEAN.
The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma. It is designed as a head-to-head comparative study where the result will show whether Ygalo is more effective, just as effective, or less effective than the current standard of care treatment option pomalidomide for late-stage RRMM patients.
“We are of the firm belief that Ygalo will help late-stage multiple myeloma patients both in terms of efficacy and tolerability. These patients have a poor prognosis and a significant medical need for more and better treatment options. We are pleased to announce that the first patient in our pivotal phase III study OCEAN has been dosed. This is a milestone for Ygalo and for us as a company, and takes us one step closer to making Ygalo available for late-stage multiple myeloma patients.” said Jakob Lindberg, CEO of Oncopeptides.